KalVista Pharmaceuticals (KALV) Enterprise Value (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Enterprise Value of -$191.5 million for Q3 2025, down 9.87% on a YoY basis from -$212.4 million in Q3 2024, and up 13.21% sequentially from -$220.6 million in Q2 2025.
KalVista Pharmaceuticals (KALV) Enterprise Value (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Enterprise Value data on file, last reported at -$191.5 million in Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value fell 9.87% year-over-year to -$191.5 million; the trailing twelve-month figure through Jul 2025 stood at -$191.5 million (down 9.87% YoY), and the FY2025 full-year result was -$220.6 million, down 4.86% from the prior year.
- Enterprise Value improved to -$191.5 million in Q3 2025, from -$220.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$50.3 million in Q1 2021 to a low of -$268.3 million in Q4 2024.
- A 5-year average of -$167.8 million and a median of -$171.7 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value plunged 287.17% in 2022 and jumped 55.97% in 2024, its largest moves.
- Tracing KALV's Enterprise Value over 5 years: stood at -$209.8 million in 2021, then surged by 41.72% to -$122.3 million in 2022, then rose by 15.62% to -$103.2 million in 2023, then slumped by 160.09% to -$268.3 million in 2024, then gained by 28.65% to -$191.5 million in 2025.
- Business Quant data shows KALV's Enterprise Value at -$191.5 million in Q3 2025, -$220.6 million in Q2 2025, and -$268.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -191.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -191.47 Mn |
| Apr 30, 2025 | -220.62 Mn |
| Dec 31, 2024 | -268.35 Mn |
| Oct 31, 2024 | -135.78 Mn |
| Jul 31, 2024 | -174.27 Mn |
| Apr 30, 2024 | -210.40 Mn |
| Jan 31, 2024 | -75.59 Mn |
| Oct 31, 2023 | -103.17 Mn |
| Jul 31, 2023 | -123.26 Mn |
| Apr 30, 2023 | -149.38 Mn |
| Jan 31, 2023 | -171.69 Mn |
| Oct 31, 2022 | -122.27 Mn |
| Jul 31, 2022 | -142.08 Mn |
| Apr 30, 2022 | -166.20 Mn |
| Jan 31, 2022 | -194.79 Mn |
| Oct 31, 2021 | -209.81 Mn |
| Jul 31, 2021 | -230.63 Mn |
| Apr 30, 2021 | -248.93 Mn |
| Jan 31, 2021 | -50.31 Mn |
| Oct 31, 2020 | -55.87 Mn |